Dolby Laboratories, Inc. (NYSE:DLB) Q1 2025 Earnings Call Transcript
Q1 2025 Earnings Call Transcript January 29, 2025 Dolby Laboratories, Inc. beats earnings expectations. Reported EPS is $1.14, expectations were $1.07. Operator: Ladies and gentlemen, thank you for standing by.
Dolby Laboratories Inc (DLB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Dolby Laboratories Inc (DLB) reports a 13% revenue increase, fueled by robust licensing performance and expanding automotive partnerships.
Dolby Laboratories (DLB) to Release Quarterly Earnings on Wednesday
Dolby Laboratories (NYSE:DLB – Get Free Report) will likely be posting its quarterly earnings results after the market closes on Wednesday, January 29th. Analysts expect Dolby Laboratories to post earnings of $1.
Dolby Laboratories Earnings Review: Q1 Summary
Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up $41.42 million from the same period last year. In the previous quarter, the company beat on EPS by $0.11, resulting in a 16.0% increase change in the share price the following day.
Dolby's Q1 Earnings & Revenues Surpass Estimates, Increase Y/Y
DLB's fiscal first-quarter 2025 performance gains from steady growth in the Licensing, and the Products and services segments.
Barrington Reaffirms Their Buy Rating on Dolby Laboratories (DLB)
Barrington analyst Patrick Sholl maintained a Buy rating on Dolby Laboratories (DLB – Research Report) today and set a price target of $100.00.
Dolby Laboratories (DLB) Tops Q1 Earnings and Revenue Estimates
Dolby Laboratories (DLB) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $1.01 per share a year ago. These figures are adjusted for non-recurring items.
Here's Why We Think Dolby Laboratories (NYSE:DLB) Is Well Worth Watching
The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus analyst forecasts for Dolby Laboratories' future EPS 100% free.
Rosenblatt Securities Sticks to Their Buy Rating for Dolby Laboratories (DLB)
In a report released yesterday, Steve Frankel from Rosenblatt Securities reiterated a Buy rating on Dolby Laboratories (DLB – Research Report),
Hosted on MSN10h
Dolby Laboratories Faces Revenue Risks Amid Licensing Reliance and Market Challenges
Dolby Laboratories (DLB) has disclosed a new risk, in the Corporate Activity and Growth category. Dolby Laboratories faces significant business ...
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from ...
news.stocktradersdaily7d
How the (DLB) price action is used to our Advantage
Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.
Knowridge7d
This test could achieve early diagnosis of dementia with Lewy bodies
A new study published in Alzheimer’s & Dementia highlights a significant step forward in diagnosing Dementia with Lewy Bodies ...
CervoMed provides update on neflamapimod DLB program
CervoMed (CRVO) provided an update on its neflamapimod development program in dementia with Lewy bodies, DLB, as part of an oral presentation ...
Nasdaq10d
Why Dolby Laboratories (DLB) is a Top Growth Stock for the Long-Term
DLB is a #2 (Buy) on the Zacks Rank, with a VGM Score of B. Additionally, the company could be a top pick for growth investors. DLB has a Growth Style Score of B, forecasting year-over-year ...